Monoclonal antibody ICR12-CPG2 conjugate

Drug Profile

Monoclonal antibody ICR12-CPG2 conjugate

Alternative Names: ICR12-CPG2; Monoclonal antibody ICR12-carboxypeptidase G2 conjugate

Latest Information Update: 12 Aug 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 12 Aug 1998 No-Development-Reported for Breast cancer in England (Unknown route)
  • 09 Jul 1996 Preclinical development for Breast cancer in England (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top